Among biologic agents, omalizumab helps reduce the frequency and severity of asthma attacks by binding to immunoglobulin E (IgE), while mepolizumab and reslizumab are monoclonal antibodies that target interleukin-5 (IL-5) and are used to treat severe eosinophilic asthma [2]. The gene discussed is IGHE; the disease is asthma.